Dimensional Fund Advisors LP lifted its position in Alexion Pharmaceuticals (NASDAQ:ALXN) by 3.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 384,441 shares of the biopharmaceutical company’s stock after acquiring an additional 12,402 shares during the quarter. Dimensional Fund Advisors LP owned 0.17% of Alexion Pharmaceuticals worth $42,850,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Xact Kapitalforvaltning AB grew its position in shares of Alexion Pharmaceuticals by 9.0% in the 4th quarter. Xact Kapitalforvaltning AB now owns 45,832 shares of the biopharmaceutical company’s stock worth $5,481,000 after acquiring an additional 3,789 shares in the last quarter. Emory University grew its position in shares of Alexion Pharmaceuticals by 36.6% in the 4th quarter. Emory University now owns 16,773 shares of the biopharmaceutical company’s stock worth $2,006,000 after acquiring an additional 4,490 shares in the last quarter. OppenheimerFunds Inc. grew its position in shares of Alexion Pharmaceuticals by 23.6% in the 4th quarter. OppenheimerFunds Inc. now owns 105,244 shares of the biopharmaceutical company’s stock worth $12,586,000 after acquiring an additional 20,098 shares in the last quarter. MANA Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals in the 4th quarter worth approximately $697,000. Finally, Cornerstone Capital Management Holdings LLC. grew its position in shares of Alexion Pharmaceuticals by 12.2% in the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 54,244 shares of the biopharmaceutical company’s stock worth $6,486,000 after acquiring an additional 5,883 shares in the last quarter. Institutional investors own 92.22% of the company’s stock.
In other Alexion Pharmaceuticals news, EVP John J. Orloff sold 2,115 shares of Alexion Pharmaceuticals stock in a transaction on Friday, June 8th. The stock was sold at an average price of $118.53, for a total transaction of $250,690.95. Following the sale, the executive vice president now owns 31,790 shares of the company’s stock, valued at approximately $3,768,068.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction dated Monday, April 30th. The stock was purchased at an average cost of $120.79 per share, for a total transaction of $1,207,900.00. Following the purchase, the director now directly owns 26,333 shares in the company, valued at approximately $3,180,763.07. The disclosure for this purchase can be found here. 4.35% of the stock is owned by insiders.
Shares of Alexion Pharmaceuticals opened at $124.15 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.86 and a current ratio of 3.35. The firm has a market cap of $27.07 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11. Alexion Pharmaceuticals has a 1-year low of $102.10 and a 1-year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.18. The firm had revenue of $930.90 million for the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.38 EPS. research analysts forecast that Alexion Pharmaceuticals will post 6.28 EPS for the current fiscal year.
Several research analysts have recently commented on the company. Deutsche Bank set a $161.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 15th. Credit Suisse Group reiterated an “outperform” rating and issued a $149.00 target price (up previously from $147.00) on shares of Alexion Pharmaceuticals in a research report on Friday, March 16th. BidaskClub upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 23rd. Nomura raised their price target on Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. Finally, Robert W. Baird set a $160.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $160.00.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.